Product
F-627
Aliases
Recombinant Human Granulocyte Colony Stimulating Factor (rh G-CSF) Fc fusion protein
2 clinical trials
2 indications
Indication
NeutropeniaIndication
Breast CancerClinical trial
A Single-Center, Open-Label, Dose-Escalation Phase I Clinical Trial of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein for Injection as an Adjuvant to Chemotherapy in Subjects With Breast CancerStatus: Completed, Estimated PCD: 2013-12-01
Clinical trial
A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic ChemotherapyStatus: Completed, Estimated PCD: 2019-09-25